BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21694609)

  • 1. Control of intragastric pH and its relationship to gastroesophageal reflux disease outcomes.
    Katz PO; Johnson DA
    J Clin Gastroenterol; 2011 Oct; 45(9):748-54. PubMed ID: 21694609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD).
    Milkes D; Gerson LB; Triadafilopoulos G
    Am J Gastroenterol; 2004 Jun; 99(6):991-6. PubMed ID: 15180715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
    Miner PB
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients.
    Weigt J; Kandulski A; Büsch F; Malfertheiner P
    Dig Dis; 2009; 27(1):68-73. PubMed ID: 19439964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving issues in the management of reflux disease?
    Yuan Y; Hunt RH
    Curr Opin Gastroenterol; 2009 Jul; 25(4):342-51. PubMed ID: 19417644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained improvement in symptoms of GERD and antisecretory drug use: 4-year follow-up of the Stretta procedure.
    Noar MD; Lotfi-Emran S
    Gastrointest Endosc; 2007 Mar; 65(3):367-72. PubMed ID: 17321232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?
    Armstrong D
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():19-26; discussion 38-9. PubMed ID: 15456460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the acidity index and integrated intragastric acidity in 645 patients presenting with gastroesophageal reflux disease symptoms.
    Blonski WC; Shih GL; Brensinger CM; Katzka DA; Metz DC
    Scand J Gastroenterol; 2006 Apr; 41(4):382-9. PubMed ID: 16635904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring.
    Sharma N; Agrawal A; Freeman J; Vela MF; Castell D
    Clin Gastroenterol Hepatol; 2008 May; 6(5):521-4. PubMed ID: 18356117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: complete gastro-oesophageal reflux monitoring - combined pH and impedance.
    Tutuian R; Castell DO
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 2():27-37. PubMed ID: 16939430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.
    Watson TJ; Peters JH
    Thorac Surg Clin; 2005 Aug; 15(3):405-15. PubMed ID: 16104131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease.
    Tefera S; Hatlebakk JG; Berstad A
    Am J Gastroenterol; 2001 Apr; 96(4):969-74. PubMed ID: 11316213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.
    Leite LP; Johnston BT; Just RJ; Castell DO
    Am J Gastroenterol; 1996 Aug; 91(8):1527-31. PubMed ID: 8759655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastroesophageal reflux disease: pathophysiology and pharmacology overview.
    Dajani EZ
    J Assoc Acad Minor Phys; 2000; 11(1):7-11. PubMed ID: 10826019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical therapy for gastroesophageal reflux disease in 2007.
    Katz PO
    Rev Gastroenterol Disord; 2007; 7(4):193-203. PubMed ID: 18192955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?
    Bruley des Varannes S; Coron E; Galmiche JP
    Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):905-21. PubMed ID: 21126703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weakly acidic reflux.
    Tack J; Blondeau K
    Dig Dis; 2009; 27(1):58-61. PubMed ID: 19439962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.